Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ: INKT )

0.5290 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 472
Open 0.5290
Bid (Size) 0.5003 (13)
Ask (Size) 0.6600 (20)
Prev. Close 0.5290
Today's Range 0.5290 - 0.5290
52wk Range 0.4632 - 1.900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer 
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire

Performance

YTD
-51.47%
-51.47%
1 Month
-23.55%
-23.55%
3 Month
-30.39%
-30.39%
6 Month
-40.56%
-40.56%
1 Year
-48.17%
-48.17%

More News

Read More
Examining the Future: MiNK Therapeutics's Earnings Outlook
Via Benzinga
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
From MiNK Therapeutics
Via GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
MiNK Reports Second Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
MiNK Reports First Quarter 2024 Results
From MiNK Therapeutics
Via GlobeNewswire
Why MiNK Therapeutics Stock Is Up 11% Monday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
From MiNK Therapeutics
Via GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
From MiNK Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.